Evidence map›Paper›PMID 41590849›Full record

ReviewJournal of cardiovascular development and disease2025

Efferocytosis: The Silent Guardian of Tissue Homeostasis and Cardiovascular Health.

Wenting Peng, Yuhao Song, Shengxi Gu, Ye Zhu, Ying Li

Abstract readReview
In one paragraph

Review in Journal of cardiovascular development and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenting PengDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0009-0009-3811-1578
Yuhao SongDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Shengxi GuDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Ye ZhuDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
Ying LiDepartment of Cardiology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid and effective clearance of apoptotic cells, known as efferocytosis, is essential for maintaining tissue homeostasis. Efferocytosis removes apoptotic cells before the occurrence of membrane rupture from which the cell contents, often inflammatory and toxic, are released into surrounding tissues. Through this way, efferocytosis protects the surrounding tissues from toxic enzymes and oxides inside the apoptotic cells as well as from cellular contents such as anti-proteinase and cystatins. Driven by the ongoing advancements in bioinformatics and molecular biology, many researchers have explored the mechanism of efferocytosis and its association with systemic diseases. Multiple studies have demonstrated that impaired efferocytosis mechanisms significantly contribute to the onset and progression of chronic inflammation. The presence of chronic inflammation significantly exacerbates the advancement of cardiovascular diseases, including atherosclerosis, myocardial infarction, heart failure subsequent to myocardial infarction, and even myocarditis. This review aims to provide a brief introduction to the mechanisms involved in cellular efferocytosis, followed by an examination of the molecular and pathway aspects of efferocytosis with the risk of cardiovascular diseases, contributing to the identification of potential therapeutic targets for related diseases.

Indexed as

apoptotic cellsatherosclerosiscardiovascular diseasesefferocytosisnecrosis

Identifiers

PMID41590849
PMCPMC12841828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.